Association Between Inflammatory Markers, Comorbidities, and Mortality in COVID‐19 Patients Treated With Tocilizumab
Journal of Medical Virology · 2026-06 · 98 (6)
DOI: 10.1002/jmv.71028 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Medical Virology, online erschienen am 22.06.2026. Verfasst von Rafaela Munari da Silva und 9 weiteren Autor:innen. Beteiligte Einrichtung: Escritório de Gestão da Prática clínica, Hospital Moinhos de Vento, Porto Alegre, Rio Grande do Sul, Brasil. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Humanized, COVID-19 Drug Treatment, COVID-19, Inflammation. Die Arbeit nennt 28 Literaturangaben.
Abstract (Originalsprache)
Tocilizumab, an interleukin‐6 receptor antagonist, has been widely used in the management of severe COVID‐19 cases, but its clinical outcomes have been variable. A retrospective cohort including 113 hospitalized adult patients with confirmed COVID‐19 treated with tocilizumab between March and October 2021 at a private hospital in southern Brazil. Demographic, clinical, and laboratory variables were collected at four time points: admission, 72 h before tocilizumab administration, 72 h after, and at hospital discharge or death. The median age was significantly higher among non‐survivors (73.0 vs. 58.5 years; p < 0.01). Cardiovascular, metabolic, pulmonary, and neoplastic comorbidities negatively impacted clinical outcomes. These patients also showed persistent elevation of inflammatory markers and organ dysfunction indicators, such as d ‐dimer, urea, and BNP. Concomitant use of corticosteroids was associated with improved survival ( p = 0.04). Age, comorbidities, and persistent elevation of inflammatory markers were associated with worse prognosis in patients treated with tocilizumab. Concomitant use of corticosteroids demonstrated a potential benefit, suggesting a synergistic effect between the therapies. These findings underscore the importance of laboratory monitoring and individualized therapeutic approaches in severe COVID‐19.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Escritório de Gestão da Prática clínica, Hospital Moinhos de Vento, Porto Alegre, Rio Grande do Sul, Brasil.
- Faculdade de Ciências da Saúde Moinhos de Vento, Porto Alegre, Rio Grande do Sul, Brasil.
- Gerencia médica, Hospital Moinhos de Vento, Porto Alegre, Rio Grande do Sul, Brasil.
- Superintendente executivo, Hospital Moinhos de Vento, Porto Alegre, Rio Grande do Sul, Brasil.
- Superintendente médico, Hospital Moinhos de Vento, Porto Alegre, Rio Grande do Sul, Brasil.
- Núcleo de Apoio à Pesquisa, Hospital Moinhos de Vento, Porto Alegre, Rio Grande do Sul, Brasil.
ORCID-Profile: Jonas Michel Wolf
Zitieren
APA
Silva, R. M. D., Soper, M. S., Neves, J. H., Maciel, C. E. A., de Melo, M. E., Pille, A., Maccari, J. G., Mutlaq, M. P., Nasi, L. A., & Wolf, J. M. (2026). Association Between Inflammatory Markers, Comorbidities, and Mortality in COVID‐19 Patients Treated With Tocilizumab. Journal of Medical Virology, 98(6). https://doi.org/10.1002/jmv.71028
Vancouver
Silva RMD, Soper MS, Neves JH, Maciel CEA, de Melo ME, Pille A, et al. Association Between Inflammatory Markers, Comorbidities, and Mortality in COVID‐19 Patients Treated With Tocilizumab. Journal of Medical Virology. 2026;98(6). doi:10.1002/jmv.71028
BibTeX
@article{Silva2026,
author = {Silva, Rafaela Munari da and Soper, Mauricio Santiago and Neves, Juliana Haider and Maciel, Carlos Emanuel Antunes and de Melo, Matheus Eduardo and Pille, Arthur and Maccari, Juçara Gasparetto and Mutlaq, Mohamed Parrini and Nasi, Luiz Antônio and Wolf, Jonas Michel},
title = {Association Between Inflammatory Markers, Comorbidities, and Mortality in COVID‐19 Patients Treated With Tocilizumab},
journal = {Journal of Medical Virology},
year = {2026},
volume = {98},
number = {6},
doi = {10.1002/jmv.71028}
}
EUVIMED